#1 Clinical Trials Search in Europe

F44/10

A groundbreaking Phase 2b clinical study is underway to assess the safety and effectiveness of TP-102, a topical bacteriophage therapy for patients with diabetic foot infections. This innovative treatment combines five specific bacteriophages (F44/10, F125/10, F770/05, F510/08, F1245/05) to target common bacterial strains found in diabetic foot ulcers. The trial aims to compare TP-102 with a placebo, both used in addition to standard care, to determine its potential in improving infection classification, wound healing, and overall patient outcomes.

Table of Contents

What is TP-102?

TP-102 is a new medication being developed to treat certain types of diabetic foot infections. It is a bacteriophage therapy, which means it uses special viruses called bacteriophages to fight bacterial infections. TP-102 is a liquid suspension that contains five different types of bacteriophages: F44/10, F125/10, F770/05, F510/08, and F1245/05.[1]

How does TP-102 work?

Bacteriophages are viruses that specifically target and destroy bacteria. Unlike antibiotics, which can kill both harmful and beneficial bacteria, bacteriophages are very selective. They only attack specific types of bacteria. In the case of TP-102, the bacteriophages are designed to target bacteria that commonly cause infections in diabetic foot ulcers.[1]

What conditions does TP-102 treat?

TP-102 is being developed to treat diabetic foot ulcers that are infected by specific types of bacteria. These bacteria include:

  • Acinetobacter baumannii: A type of bacteria that can cause serious infections, especially in people with weakened immune systems.
  • Pseudomonas aeruginosa: Another type of bacteria that can cause severe infections, particularly in wounds.
  • Staphylococcus aureus: A common type of bacteria that can cause a range of infections, from minor skin infections to more serious conditions.[1]

Current Research on TP-102

TP-102 is currently being studied in a Phase 2b clinical trial. This means that researchers are testing the safety and effectiveness of the medication in a larger group of patients with diabetic foot infections. The study is comparing TP-102 to a placebo (a treatment with no active ingredients) when used in addition to standard care for diabetic foot infections.[1]

Who can participate in the TP-102 study?

The study has specific criteria for who can participate. Some of the main requirements include:

  • Being 18 years or older
  • Having a diagnosis of diabetes (Type 1 or Type 2)
  • Having a diabetic foot infection that meets certain criteria, such as being present for at least 3 weeks and having a specific level of severity
  • Having an infection caused by one of the bacteria that TP-102 targets

There are also several factors that would prevent someone from participating in the study, such as being pregnant or breastfeeding, having certain types of cancer, or participating in other clinical trials.[1]

What are the goals of the TP-102 study?

The main goals of the study are to:

  1. Evaluate the safety and tolerability of TP-102 compared to a placebo
  2. Determine if TP-102 can improve the classification of diabetic foot infections (using a system called IWGDF/IDSA)
  3. Assess the effects of TP-102 on wound healing

The researchers will also look at other factors, such as changes in laboratory tests related to infection, how well TP-102 eliminates the target bacteria, and improvements in wound infection scores.[1]

Potential Benefits of TP-102

While the study is still ongoing and the full benefits of TP-102 are not yet known, researchers hope that this new treatment could offer several advantages:

  • Targeted treatment: By using bacteriophages that specifically target the bacteria causing the infection, TP-102 might be able to treat infections more effectively than traditional antibiotics.
  • Improved wound healing: One of the study’s goals is to see if TP-102 can help diabetic foot ulcers heal faster.
  • Reduced antibiotic use: If successful, TP-102 could provide an alternative to antibiotics for some types of infections, which could help address the growing problem of antibiotic resistance.

It’s important to remember that TP-102 is still being studied, and more research is needed to confirm its safety and effectiveness. If you have a diabetic foot infection, continue to follow your doctor’s advice for treatment and care.[1]

Aspect Details
Study Type Phase 2b clinical study
Treatment TP-102 (bacteriophage therapy)
Administration Topical application on wound
Target Condition Diabetic foot infections
Target Bacteria Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus
Primary Objectives Safety, tolerability, clinical improvement in infection classification, effects on wound healing
Key Inclusion Criteria Adults with diabetes, specific HbA1c levels, presence of target bacterial strains
Duration Up to 31 days of treatment
Comparison TP-102 vs. Placebo, both in addition to Standard of Care

FAQ

  • What is TP-102 and how does it work? TP-102 is a topical bacteriophage therapy consisting of five specific bacteriophages. It works by targeting and eliminating bacteria commonly found in diabetic foot infections, such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus.
  • Who is eligible for this clinical trial? Eligible participants are adults (18 years or older) with diagnosed diabetes mellitus, a glycosylated hemoglobin (HbA1c) value of 12.0% or less, and a diabetic foot infection meeting specific criteria, including the presence of at least one target bacterial strain susceptible to TP-102.
  • What are the main objectives of the study? The main objectives are to evaluate the safety and tolerability of TP-102 compared to placebo, assess its effectiveness in improving diabetic foot infection classification, and determine its effects on wound healing, all in addition to standard care.
  • How is the treatment administered? TP-102 is administered topically, meaning it is applied directly to the wound or infected area on the foot.
  • What are the potential benefits of participating in this trial? Participants may benefit from a potentially more effective treatment for their diabetic foot infection, which could lead to improved wound healing, reduced infection severity, and better overall foot health. However, as with all clinical trials, there is no guarantee of personal benefit.

Ongoing Clinical Trials on F44/10

  • Study on the Safety and Effectiveness of TP-102 for Treating Diabetic Foot Infections in Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

Glossary

  • Bacteriophage: A virus that infects and replicates within bacteria, potentially killing them. In this context, bacteriophages are used as a therapeutic agent to target specific bacterial infections.
  • Diabetic Foot Infection: An infection occurring in the foot of a person with diabetes, often associated with foot ulcers and potentially leading to serious complications if left untreated.
  • IWGDF/IDSA classification: A system used to categorize the severity of diabetic foot infections, developed by the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America.
  • Standard of Care (SoC): The typical treatment or care given to patients with a specific condition, based on current medical knowledge and practices.
  • Topical administration: Application of a medication or treatment directly to a specific area on the body's surface, such as the skin or a wound.
  • Phase 2b clinical study: A stage of clinical research that focuses on evaluating the effectiveness and side effects of a new treatment in a larger group of patients.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to compare against the actual treatment being studied.
  • Glycosylated hemoglobin (HbA1c): A measure of average blood sugar levels over the past 2-3 months, used to diagnose and monitor diabetes.
  • PEDIS classification: A system used to assess diabetic foot ulcers based on five categories: Perfusion, Extent, Depth, Infection, and Sensation.
  • Treatment Emergent Adverse Events (TEAEs): Any unfavorable or unintended sign, symptom, or disease that appears or worsens after starting a medical treatment in a clinical study.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-tp-102-for-treating-diabetic-foot-infections-in-patients/